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Background: The increment of resistant strains to commonly used antibiotics in clinical practices places in
evidence the urgent need to search for new compoundswith antibacterial activity. The adaptations that Antarctic
microorganisms have developed, due to the extreme environment that they inhabit, promote them as a potential
new source of active compounds for the control of microorganisms causing infections associated with health
care. The aimof this studywas to evaluate the antibacterial activity of an ethanol extract of the Antarctic bacterium
Janthinobacterium sp., strain SMN 33.6, against nosocomial multi-resistant Gram-negative bacteria.
Results: Inhibitory activity against human Gram-negative bacterial pathogens, with concentrations that varied
between 0.5 and 16 μg ml-1, was demonstrated.
Conclusions: The ethanolic extract of Janthinobacterium sp. SMN 33.6 possesses antibacterial activity against
a chromosomal AmpC beta-lactamase-producing strain of Serratia marcescens, an extended-spectrum
beta-lactamase-producing Escherichia coli and also against carbapenemase-producing strains of Acinetobacter
baumannii and Pseudomonas aeruginosa. This becomes a potential and interesting biotechnological tool for the
control of bacteria with multi-resistance to commonly used antibiotics.© 2014 Pontiﬁcia Universidad Católica de Valparaíso. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
In the mid-twentieth century, before antibiotics were introduced,
patients with bacteremia had low probabilities of survival. The
discovery of antibiotics and development of new compounds reversed
this pessimistic prognosis. In the last decade the number of antibiotic
multi-resistant bacterial strains as etiologic agents of infectious diseases
has increased at an alarming rate; challenging physicians to ﬁnd an
anti-infective therapy that ensures an effective result [1]. The selective
pressure exerted by the use of antimicrobials reaches greater dimensions
in hospital settings with bacterial pathogens acquiring new resistance
mechanisms, facilitating the selection, accumulation, and dissemination
of antibiotic resistance genes among the bacterial population [2,3].evier
vena).
d Católica de Valparaíso.
paraíso. Production and hosting by ElThis problem places an urgent necessity of ﬁnding new and more
effective antibiotic drugs with activity against multi-resistant and,
moreover, pan-resistant bacteria that has become a critical concern
in public health [4,5]. Despite the emergency, the progress in the
development of these agents has been slow and thenumber of approved
new antimicrobials per year has been gradually decreasing [6,7].
Extremophilemicroorganisms producemolecules adapted to unusual
life conditions and have been recognized as an important source of new
biologic products [8]. Various studies have established that extremophiles
represent a new and promising source to search for novel antibacterial
molecules, although only a small fraction of these diverse biological
compounds have been studied [9].
The aim of this investigation was to evaluate the inhibitory capacity
of an ethanolic extract obtained from an Antarctic bacterial strain,
identiﬁed within the Genus Janthinobacterium, against human bacterial
pathogens isolated from Chilean hospitals, and multi-resistant to
commonly used antibiotics in human medicine.
2. Materials and methods
2.1. Bacterial isolate
The bacterial strain SMN33.6 used in this studywas isolated in 2007,
from a soil sample in Fildes Peninsula (62°12′S, 58°57′W) located insevier B.V. Open access under CC BY-NC-ND license.
Table 1
In vitro determination of the minimum inhibitory concentration (MIC) and the minimum
bactericidal concentration (MBC) of ethanol extract of the strain Janthinobacterium sp.
SMN 33.6 against multi-resistant nosocomial isolates.
Multi-resistant strains Strain code MIC (μg ml-1) MBC (μg ml-1)
A. baumannii AB-1 (OXA-58a) 1 2
E. coli EC-325 (ESBL) 0.5 2
E. coli EC-241 (ESBL) 1 16
K. pneumoniae KB-503 (ESBL) 16 16
K. pneumoniae KB-495 (ESBL) 16 16
P. aeruginosa P-145 (VIM-2a) 1 16
S. marcescens S-41 (AmpC) 2 2
S. marcescens S-32 (AmpC) 0.5 2
a Carbapenemases; ESBL: extended-spectrum beta-lactamase; AmpC: chromosomal
AmpC beta-lactamase.
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inoculated in R2A agar and cultivated at 15°C.
2.2. Ampliﬁcation of 16S rRNA gene and phylogenetic analysis
To identify and characterize phylogenetically the strain SMN 33.6,
DNAwas extracted from a liquid culture according to the basic protocol
described by Wilson [10]. The gene 16S rRNA was ampliﬁed by PCR,
using standard primers 16S Fw (5′-AGAGTTTGATCCTGGCTCAG-3′)
and 16S Rv (5′-CGGTTACCTTGTTACGACTT-3′). We used the reverse
primers to obtain the complete and correct sequence of 16S rRNA
CR [R] (5′-CTTGTGCGGGCCCCCGTCAATTC-3′) [11]. The PCR product
was puriﬁed using the AxyPrep PCR Clean-up kit (Axygen Biosciences)
and sequenced at Macrogen (Korea).
To determine the phylogenetic proximity to the SMN 33.6 strain, the
molecular identiﬁcation was done through a similarity proﬁle of the
gene sequence that encode for the 16S rRNA. The sequence was edited
with the IT program Sequencher (Gene Codes Corporation) and the
similarities were analyzed in the data base GenBank NCBI (National
Center for Biotechnology Information). A phylogenetic tree was created
using the Bosque program [12]. The method used corresponded to the
maximum likelihood, using a GTR method.Fig. 1. Phylogenetic analysis based on maximum likelihood phylogenetic tree of 16S rDNA seq
Janthinobacterium and Duganella strains. Numbers at nodes are support values (bootstrap valu2.3. Biochemical characterization of the SMN 33.6 strain
A morphologic and biochemical characterization was performed
with API 20NE and API ZYM (Biomerieux) kits, according to the
manufacturer's instructions, and growth parameters at different
temperatures andpHswere also studied. Its behavior against commonly
used antibiotics in clinical practice was also determined by an agar
diffusion method according to the Clinical and Laboratory Standards
Institute [13].
2.4. Chemical characterization of the ethanol extract
To obtain secondarymetabolites of a polar soluble nature in ethanol,
bacterial mass obtained from a solid culture medium (R2A agar) was
transferred to a 50 ml tube with absolute ethanol, in a ratio of 100 mg
of bacterial mass in 1 ml of ethanol [14]. The cell mixture with ethanol
was submitted to ultrasonication for 1 h using a Ney Ultrasonik
57H, in order to cause cell rupture and obtain soluble material [15].
Afterwards, the sample was separated by centrifuge and the supernatant
was concentrated by lyophilization. Finally, the concentrate was
resuspended in 70% ethanol.
The extractwas analyzed byhigh performance liquid chromatography
(HPLC) in a Jasco machine with a multi-wavelength detector and
equipped with a C18 column (Kromasil 100-5C18 250 × 4.6 mm). The
separation was done in a gradient mobile phase from 50:50 to 75:25
methanol:water, with a ﬂow of 1 ml min-1 at room temperature. The
volume of the injected sample was 100 μl and the running time was
20 m. The absorption spectrum, in the UVvisible range (200–800 nm)
was studied using a Shimadzu UV-1603 spectrophotometer.
2.5. Janthinobacterium sp. SMN 33.6 antibacterial activity assay
The strains used in the initial assays of antimicrobial activity
were Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 25923,
Salmonella typhimurium ATCC 14028 and Kocuria rhyzophila ATCC
9341 from the bacterial collection of the Laboratory of Investigation in
Antibacterial Agents from the Department of Microbiology at theuences showing the estimated phylogenetic relationships of strain SMN 33.6 with other
es).
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included, and corresponded to strains isolated from clinical specimens
in several Chilean hospitals (Table 1). The cultures were done in a
nutritional medium LB at 37°C. Growth was evaluated by measuring the
optical density at 600 nmwith a Shimadzu UV-1603 spectrophotometer.
The screening of inhibitory activity was studied by the agar spot test
described by Fleming et al. [16],withmodiﬁcations, that involved culture
of the strain SMN 33.6 on nutritive agar, in a tip shaped form until the
growth reached 2–4 mm, then a second layer of LB agar (10 ml) with
50% agar was added, inoculated with 100 μl of the pathogenic bacterial
strain to test, in exponential growth phase. The plates were incubated
at 37°C for 24 h. The antibacterial activity was evaluated by the presence
of an inhibition zone around the colony of the strain SMN 33.6.
The minimum inhibitory concentration (MIC) was evaluated with a
standard method of serial microdilution inMueller–Hinton broth (MH)
using microtiter plates. Each assay was performed in triplicate and
the value repeated at least two times was considered as the MIC. The
bacterial inoculum used was 5 × 105 UFC ml-1, obtained from a 0.5
McFarland turbidity standard (1.5 × 108 UFC ml-1). Microtiter plates
were incubated at 35°C for 24 h and MIC was registered as the lowest
concentrationwithout turbidity. Theminimumbactericidal concentrationFig. 2. Puriﬁcation and characterization of bacterial pigment from Janthinobacterium sp. SMN 3
and the compounds C3 and C4 (violacein) are themajor peaks. (b) Absorption spectra of pigmen(MBC) was determined, transferring broth fromwells without growth to
a MH agar plate without extract and incubating at 35°C for 24 h.
3. Results and discussion
From a total of 237 strains isolated on R2A agar, from soil samples
collected in King George Island, Antarctica (62°11′3.31″S, 58°56′1.18″
W), a violet Gram-negative bacteria was selected, and named as strain
SMN 33.6. The initial assay of antibacterial activity demonstrated growth
inhibition of E. coli ATCC 25922, S. aureus ATCC 25923, S. typhimurium
ATCC 14028 and K. rhyzophila ATCC 9341, which was veriﬁed by clear
inhibition zones surrounding the SMN 33.6 strain colony (data not
shown). The potent inhibition that the strain showed in the “Agar Spot
Test” assay evidenced the production of compounds with antibacterial
activity capable of diffusion in a solid medium and active against
Gram-positive and Gram-negative bacteria.
The culture of SMN 33.6 on agar R2A produced colonies with
violet pigmentation, not observed in liquid cultures of the same
medium, so the contact with a substrate could activate higher
production of this characteristic pigment. The strain corresponded
to an oxidase producing rod-shaped bacterium. The biochemical3.6. (a) HPLC of ethanol extract. The C18 column was used to separate the different peaks,
ted compounds, C3, C4 (violacein) and C5with amaximum in the visible range at 576 nm.
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nitrate, and assimilate glucose, arabinose, mannose, mannitol,
maltose, potassium gluconate and malate. The assay with the API
ZYM gallery demonstrated positive activity for alkaline phosphatase,
naphthol-AS-BI-phosphohydrolase and α-glycosidase. The optimum
growth temperature was 20°C which occurred during all the studied
range of pH (5–9), pH 7 being the optimum.
In assays for molecular identiﬁcation of SMN 33.6, a PCR product of
approximately 1500 bp was ampliﬁed from the 16S rRNA gene, and a
sequence of 1366 bp was obtained (Genbank Accession Number:
JX624164). According to the homology analysis of nucleotide sequence,
this strain exhibits a 97.4% similarity with the species Janthinobacterium
lividum. However, there is also a high homology with strains from
the genera Duganella (99%) and from this, the species Duganella
violaceinigra is reported as a producer of the violacein pigment. This
latest bacteria is a mesophilic bacteria with optimum growth between
28 and 30°C [17], while SMN 33.6 was not able to grow at these
temperatures. The phylogenetic tree corroborated this similarity,
grouping this strain with others of the Genus Janthinobacterium
(Fig. 1). However, the results of API 20 NE present differences
with information for the J. lividum NCTC 9796 strain in respect to the
hydrolysis of aesculin and gelatin and assimilation of trisodium citrate,
which would indicate atypical strains of the species [18,19].
The results of the behavior against some antibiotics indicate that
SMN 33.6, presents susceptibility to cefotaxime, kanamycin,
amikacin, gentamicin, tetracycline, nalidixic acid, ciproﬂoxacin and
rifampicin. It possesses intermediate susceptibility to streptomycin
and chloramphenicol, and is resistant to ampicillin, cephalothin,
cefoxitin, cefuroxime and trimethoprim. Resistance to beta-lactam
antibiotics could be explained by the production of an enzymebelonging
to a new molecular class B metallo-β-lactamase, as was reported for an
environmental strain of J. lividum by Rossolini et al. [20].
Strains of Genus Janthinobacterium with violet pigmentation have
been isolated from Antarctica since 1981 [18], studying characteristics
associated to its growth and physiology. On the other hand, various
violet pigmented bacteria, obtained from temperate environments,
have been studied in regard to the biological properties of the violet
pigment they produced. This pigment is known as violacein which is
an indole type of compound, derived from tryptophan metabolism
and is produced by various bacteria such as Chromobacteriumviolaceum,
Pseudomonas luteoviolacea, Duganella sp. and Collimonas sp., as well as,
the already mentioned Genus Janthinobacterium [21,22]. This pigment
is intracellular and the most important disadvantage to use it as a
therapeutic compound is its poor solubility in water and biological
ﬂuids; therefore, it diffuses to a lesser degree than polar compounds in
agar medium, so the activity obtained in the agar spot test could be
due to a sum of antagonistic activities of compounds of other nature,
such as diffusible peptides or enzymes [23,24,25].
The ethanol extract obtained from the strain SMN33.6 biomass, has a
violet coloration and presents absorption peaks at 575 and 375 nm and
minimum at 431 nm. The chromatogram obtained by HPLC, shows the
presence of ﬁve majority compounds, three of them colored, with maxi-
mum absorption close to 575 nm, which correspond to maximum ab-
sorption reported for violacein by Durán et al. [26]. The retention times
are 11.7, 13.1 and 16.1 min (Fig. 2). However, the similitude in the ab-
sorption spectrum of these three compounds, and the difference in the
time of retention, demonstrated that these compounds are different
from each other. To identify violacein, the test described by Gillis and
Logan [27], was carried out. Sulfuric acid was added at 10% (v/v), chang-
ing the coloration of the compounds, indicated as C3 and C4, and turning
from violet to green. The C3 compound showed a maximum at 699 nm
and a minimum at 489 nm of absorbance after the acid treatment,
while the C4 compound had a maximum at 700 nm and a minimum at
497 nm. These results are consistent with violacein behavior which has
a reported absorbance of 700 nmas amaximumand502 nmas themin-
imum. By adding sodium hydroxide, the solution that contains violaceinmust turn into a green color and then to a reddish brown color. The C4
compound changed color as indicated, while the C3 turned immedi-
ately to reddish brown. Therefore, it is deduced that the C4 com-
pound collected corresponds to violacein, which is 35% of the
sample. The collected C3 compound corresponds to compounds de-
rived from this one, such as oxyviolacein or deoxyviolacein [15,28].
However, the compound indicated as C5 did not change color with
the acid and base treatments, indicating that this could be a new com-
pound and future studies to identify and clarify its chemical structure
are needed.
The violacein presents a wide antimicrobial spectrum since it has
demonstrated activity againstGram-negative andGram-positive bacteria,
being more active upon these last ones, as well as antifungal activity
against Rosselinia necatrix, a phytopathogenic fungus [26]. On the other
hand, antimycobacterial activity in vitro against Mycobacterium
tuberculosis [28], mild antiparasitic activity against Trypanosoma cruzi,
and activity against tumor cells have been demonstrated; and when
adding 10% deoxyviolacein, it also has antiviral activity against theHerpes
simplex virus [29]. Lately, it has been demonstrated that the purple
pigment also has antibacterial properties against methicillin resistant
Staphylococcus aureus, proposing a possible binding to the bacterial
DNA as mechanism of action [25]. These reports demonstrate
a high biotechnological potential associated to the use of this
compound in medicine, even though C. violaceum has been reported
as an etiologic agent of serious infections in humans and it represents
a difﬁcult-to-treat entity, so special attention is required [30]. Violacein
would not be involved in its pathogenicity; therefore, isolating new
violacein producing strains or othermoleculeswith antimicrobial activity,
could contribute to the diversiﬁcation in the application of natural
products produced by bacteria.
The analyzed extract showed antibacterial activity over eight
multi-resistant strains of Gram-negative bacilli isolated from clinical
specimens in Chilean hospitals, exhibiting different MIC. The assayed
species corresponded to an Acinetobacter baumannii strain and a
Pseudomonas aeruginosa strain, both carbapenemase producers;
two strains of E. coli and two strains of Klebsiella pneumoniae, producing
extended-spectrumβ-lactamases (ESBL) and twomulti-resistant strains
of Serratia marcescens producing a chromosomal AmpC beta-lactamase
(Table 1). The MIC values ranged between 0.5 and 16 μg ml-1. The
minimum MBC varied between 2 and 16 μg ml-1 (Table 1).
The majority of the strains tested correspond to multi-resistant
Gram-negative bacilli, that produce ESBL and carbapenemases, which
are important human pathogens and main etiologic agents causing
hospital-acquired infections in Chile and worldwide. ESBL producing
strains and A. baumannii have been catalogued by the Antimicrobial
Availability Task Force (AATF) of the Infectious Diseases Society of
America (IDSA) as particularly problematic pathogens [5]. In recent
years, a progressive increase in isolation of these bacteria has been
observed in outbreaks in several hospitals, with an elevated morbidity
and mortality. In the last decade strains of A. baumannii often exhibiting
multidrug resistance have emerged as a signiﬁcant clinical problem
worldwide [31,32,33].
The extract showed a low MIC, 1 mg ml-1, against the strain of
P. aeruginosa tested, a VIM-2 carbapenemase-producer, which also
presents multiple resistance to antibiotics and has limited therapeutic
alternatives [34]. The metallo-enzymes, belonging to the IMP and VIM
family are more frequent and are found disseminated worldwide.
These have the capacity to hydrolyze all the penicillins, cephalosporins,
and carbapenems [35].
S. marcescens is increasingly recognized as a cause of morbidity in
nosocomial settings. It can act as an etiologic agent in several infections
affecting humans. When transmitted to a patient, it colonizes wound
surfaces, mucosal areas or indwelling devices [36]. The strains are
resistant to rifampicin, penicillin, ampicillin, amoxicillin, tetracycline,
amoxicillin–clavulanic acid, cefazolin, cefamandole, polymyxin B, colistin,
fusidic acid, lincosamides, streptogramins, daptomycin, linezolid, and
5G. Asencio et al. / Electronic Journal of Biotechnology 17 (2014) 1–5cefuroxime [37]. The strain extract was capable of inhibiting growth of
both strains of S. marcescens included in this study with an MIC of 0.5
and 2 μg ml-1.
The activity of the ethanolic extract against E. coli strains cannot be
explained for the violacein presence. De Azevedo et al. [38] have been
reported a low acute toxicity of puriﬁed violacein against strains of this
specie.Wang et al. [39] reported strong activities of violacein derivatives,
deoxyviolacein and oxyviolacein against Gram-positive bacteria and
antifungal activity. Oxyviolacein also showed activity against Phytophtora
capsici, a pathogen of vegetable crops. This result suggest that there are
different compounds present in the chromatogram which could be
exerting such inhibitory activity or acting synergistically with violacein.
The results obtained in this study demonstrate the biotechnological
potential of natural products obtained from Antarctic microorganisms
as a tool for the control of hospital-acquired infections (infections
associated with health care)which are difﬁcult to treat.Wedemonstrate
that the ethanolic extract of Janthinobacterium sp. SMN 33.6 could be
useful in the growth control of bacterial pathogens, even against those
multi-resistant strains isolated from hospitals in agreement with that
reported by Huang et al. [25] but against Gram-negative bacilli. Future
studies should be conducted concerning the identiﬁcation of all the
compounds present in the extract and the evaluationof their antibacterial
activity, to clarify its nature, mechanism of action and regulation.
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